Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes-Reference-Cited by-同舟云学术

Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes

Published:2020-05-26 Issue:10 Volume:61 Page:2511-2514
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Cohen Jonathan¹,Palumbo Alison¹,Wing Jason¹,Heinrich Michael C.²^ORCID

Affiliation:

1. Pharmacy Services, Oregon Health & Science University, Portland, OR, USA;

2. Portland VA Health Care System and OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1768380

Reference15 articles.

1. Leukemia – chronic myeloid – CML guide. Cancer.Net. March; 2018; [cited 2018 Oct 10]. Available from: https://www.cancer.net/cancer-types/leukemia-chronic-myeloid-cml

2. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

3. National Comprehensive Cancer Network. Chronic myeloid leukemia (version 1.2019); 2018; [cited 16 Oct 2018]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf

4. null

5. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment-Free Remission—A New Aim in the Treatment of Chronic Myeloid Leukemia;Journal of Personalized Medicine;2021-07-22